[1]胡善联.中国医保药品价格谈判回顾和展望[J].卫生经济研究,2024,41(01):9-13.
　HU Shanlian.Review and Prospects of Medical Insurance Price Negotiation in China[J].Journal Press of Health Economics Research,2024,41(01):9-13.
点击复制

中国医保药品价格谈判回顾和展望
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年01期
页码:
9-13
栏目:
药物经济
出版日期:
2024-01-03

文章信息/Info

Title:
Review and Prospects of Medical Insurance Price Negotiation in China
作者:
胡善联1
1.复旦大学公共卫生学院，上海 200000
Author(s):
HU Shanlian
School of Public Health, Fudan University, Shanghai 200000, China
关键词:
药品价格谈判; 战略购买; 价值谈判; 药物经济学; 评审条件
Keywords:
drug price negotiation;  strategic procurement;  value-based negotiation;  pharmacoeconomics;  review criteria
分类号:
R19
文献标志码:
A
摘要:
目的：总结2018—2023年中国医保药品价格谈判的实践经验，对未来的工作提出建议。方法：通过文献回顾、收集官方公布的数据和网络报道资料，对当前医保药品价格谈判的政策和实践进行总结分析。结果：谈判药品平均降价50%~60%，但也存在有待解决的问题。未来医保药品价格谈判工作需要更加关注价值谈判组织体系、标准和方法的建立，重视价值谈判的立法和规制，使价格谈判工作更加公正、公平和透明化。结论：我国的药品价格谈判成绩斐然，充分发挥了政府主导和市场机制的作用，通过价值谈判保障了创新药物的可得性和可及性，在新药需求无限性和医保基金有限性之间找到了平衡点。
Abstract:
Objective To sum up the practical experience of medical insurance drug price negotiation between 2018 and 2023 and make some suggestions for future improvements. Methods Through literature review, official data collection and public opinion analysis from website. Results The average rate of price reduction is at the range of 50%-60%. The evaluation conditions, evaluation indexes, evaluation methods, thresholds and unfinished agenda are introduced as well. The author puts forward three suggestions for the future drug price negotiation in China, i,e., the establishment of the organization system for value negotiation, standards and methods of price negotiation, legislation and regulation of value negotiation in order to make the drug price negotiations more scientific, fairness and transparency. Conclusion China has made remarkable achievements in drug price negotiation, giving full play to the role of government-led and market mechanism, and providing Chinese people with the availability and accessibility of innovative drugs through the present value negotiation. A balance has been reached between the unlimited demand for innovative drugs and the limited availability of health insurance funds.

参考文献/References:

[1] 陈金甫.实施价值导向的医保战略性购买[J].财经杂志，2017（12）：105-110.
[2] 基本医疗保险用药管理暂行办法（国家医疗保障局令第1号）[EB/OL].http://www.gov.cn/gongbao/content_5547646.htm.
[3] 国家卫生健康委卫生发展研究中心.2022中国卫生总费用研究报告（内部资料）[R].
[4] DiStefno M J,et al.Assessing the added the rapeutic nenefit of ultra-expensive drugs[J].Value Health Regional Issues,2021,24(03):397-403.
[5] Remy Claire,et al.How will recent pricing regulations impact the gobal pricing landscpe?[J].Poster No.HPR17.2023 ISPOR Europe conference.
[6] Libanore A,et al.A conceptual modeling framework for manufacturers to navigate the inflation reductionactand to negotiate a“FairMaximum Price”[J].Poster No.HPR 122.2023 ISPOR Europe.
[7] 邱越，王艾冰，徐诗瑜.2023年医保谈判结束:寻求价格与创新之间的“最大公约数”[EB/OL].[2023-11-23].https://www.thepaper.cn/newsDetail_forward_25397762.
[8] Zhou Jing，et al.Impact of price negotiation on the pricing of anticancer drugs in China[J].Poster No.HPR 139.2023 ISPOR Europe.
[9] 刘颍,杨健.国家药品价格谈判的法律规范框架研究[J].中国卫生政策研究,2017，10（06）：20-24.

相似文献/References:

[1]常 峰,崔鹏磊*,张舰云,等.全球视角下药品风险分担协议政策分析[J].卫生经济研究,2016,(08):39.
[2]马 蓉,汤少梁,冯莉钧.药品价格多方谈判主体及其事权划分研究[J].卫生经济研究,2017,(03):8.
[3]丁锦希,钭江苑,李 伟.英国创新药品价格协议研究[J].卫生经济研究,2017,(05):40.
[4]胡善联.购买有价值的医疗卫生服务[J].卫生经济研究,2019,(02):3.
　HU Shan-lian.Purchasing Value-based Medical and Health Services[J].Journal Press of Health Economics Research,2019,(01):3.

更新日期/Last Update: 2024-01-03